Report
Grifols B : Q3 earnings notably below expectations. FY 2024 guidance reiterated
>Biopharma sales momentum improves… - Sales grew by +12% or +12% cc (vs +9% cc in Q2) to € 1.8bn (in line). Momentum improved sequentially and unlike Q2, where it was mostly explained by Bio-supplies/Diagnostic, it is now Biopharma leading the growth (+12%cc in Q3 vs +9% in Q2). Bio Supplies (+49% cc in Q3 vs +93% in Q2) deteriorated sequentially yet maintained a very solid pace. Diagnostic (+1% cc in Q3 vs +1% in Q2) kept the very modest pace seen in Q2 (-3% cc in Q3...
Underlying
Grifols S.A. Pref Class B
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Juan Ros-Padilla
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.